“Fluorinated drugs” represent a vast and clinically indispensable class of pharmaceuticals—from fluoroquinolone antibiotics like levofloxacin, to antifungal agents such as fluconazole and voriconazole, to topical corticosteroids like fluocinonide, and more recently, ophthalmic formulations containing perfluorohexyloctane. Yet the prefix “fluoro-” often triggers public concern, evoking associations with dental fluorosis or skeletal fluorosis—conditions linked to excessive environmental fluoride exposure. This raises a critical clinical question: Are fluorinated medications safe for long-term use? The answer is neither uniformly affirmative nor dismissive; rather, it hinges on precise distinctions among chemical structure, pharmacokinetic behavior, route of administration, and duration of therapy.
Fluorinated drugs are not a monolithic group. They fall broadly into two categories: first, conventional fluorinated compounds—typically bearing one or a few fluorine atoms incorporated into otherwise organic scaffolds (e.g., fluoroquinolones, triazole antifungals); and second, highly fluorinated substances belonging to the broader class of per- and polyfluoroalkyl substances (PFAS), characterized by multiple carbon–fluorine bonds across extended alkyl chains. These structural differences translate into fundamentally divergent safety profiles, particularly regarding long-term systemic exposure.
The safety concerns surrounding traditional fluorinated drugs are well documented and drug-class-specific. Fluoroquinolones carry the most prominent long-term risks: in July 2017, China’s National Medical Products Administration (NMPA) mandated black-box warnings in product labeling for systemic fluoroquinolones, citing irreversible adverse effects—including tendinitis and tendon rupture, peripheral neuropathy, and central nervous system disturbances. Triazole antifungals, including fluconazole and voriconazole, pose primary long-term hepatotoxicity risks, necessitating periodic liver enzyme monitoring during extended treatment. Topical fluorinated corticosteroids, while largely limited to local adverse effects (e.g., skin atrophy, telangiectasia) when used appropriately, may still contribute to systemic absorption—particularly with high-potency agents, occlusive dressings, or prolonged application over large surface areas.
A growing area of scientific scrutiny involves PFAS-derived pharmaceuticals. Due to the exceptional strength and stability of carbon–fluorine bonds, PFAS compounds resist enzymatic degradation and environmental breakdown—earning them the label “forever chemicals.” As highlighted in a comprehensive review published in *Environmental Health Perspectives*, PFAS bioaccumulate in human tissues, with elimination half-lives strongly correlated with carbon-chain length; for instance, perfluorohexanesulfonic acid (PFHxS) exhibits an estimated human elimination half-life of approximately 8.5 years. Further research, including a recent synthesis in *Environmental and Occupational Medicine*, confirms that PFAS exposure is associated with multisystem toxicity—including hepatorenal injury, immunosuppression, reproductive dysfunction, metabolic dysregulation, neurotoxicity, and potential carcinogenicity.
In China, at least one PFAS-structured ophthalmic agent—perfluorohexyloctane—has received regulatory approval. However, robust post-marketing data on its systemic accumulation and long-term safety profile following repeated dosing remain limited. This knowledge gap underscores the need for vigilant pharmacovigilance and prospective cohort studies.
Clinical decision-making around long-term fluorinated drug use must therefore be guided by four key considerations:
First, chemical classification matters. Conventional low-fluorination drugs—when prescribed at appropriate doses and durations—generally present manageable risk–benefit ratios. In contrast, PFAS-based therapeutics warrant heightened caution due to their intrinsic persistence and bioaccumulative potential.
Second, route of administration significantly modulates systemic exposure. Topical or localized delivery minimizes systemic absorption—but does not eliminate it entirely. Even ophthalmic or dermatologic formulations may contribute to cumulative body burden, especially with chronic use.
Third, dose and duration are non-negotiable determinants of safety. Fluoroquinolones, for example, should never be used chronically without compelling indication and rigorous risk assessment; short-course regimens remain standard of care.
Fourth, individualized monitoring is essential. Patients receiving prolonged courses of triazole antifungals or emerging PFAS-containing therapies require structured follow-up—including hepatic function tests, renal panels, immune markers where relevant, and, potentially, biomonitoring for PFAS serum concentrations as validated assays become clinically accessible.
Fluorinated drugs have undeniably advanced therapeutic precision across infectious disease, dermatology, ophthalmology, and beyond. Yet the adage “all drugs carry inherent risk” remains foundational. With PFAS-based pharmaceuticals, the convergence of extreme molecular stability, slow biological clearance, and multifaceted toxicological endpoints demands a precautionary, evidence-informed approach—grounded in shared decision-making, transparent risk communication, and ongoing surveillance.